FY2026 EPS Estimates for Journey Medical Lowered by Analyst

Key Points

• HC Wainwright lowered Journey Medical’s FY2026 EPS forecast to a loss of $0.06 per share from $0.05 previously, below the $0.02-per-share consensus loss estimate.
• Second-quarter results beat expectations: the company reported a $0.01-per-share loss versus the anticipated $0.02 loss, while revenue of $18.51 million exceeded the $18.36 million estimate.
• Analyst sentiment remains mixed: B. Riley raised its price target to $15 from $12 and maintained a Buy rating, but the overall analyst consensus is Hold with a $14 target price.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - Investment analysts at HC Wainwright decreased their FY2026 earnings per share estimates for shares of Journey Medical in a research report issued on Thursday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings per share of ($0.06) for the year, down from their previous forecast of ($0.05). The consensus estimate for Journey Medical's current full-year earnings is ($0.02) per share.

Journey Medical (NASDAQ:DERM - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. Journey Medical had a negative return on equity of 20.23% and a negative net margin of 8.95%.The business had revenue of $18.51 million during the quarter, compared to analyst estimates of $18.36 million.

Several other equities research analysts also recently commented on DERM. Wall Street Zen upgraded Journey Medical from a "hold" rating to a "buy" rating in a report on Saturday, June 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Journey Medical in a report on Friday, July 17th. Finally, B. Riley Financial reiterated a "buy" rating and issued a $15.00 target price (up from $12.00) on shares of Journey Medical in a report on Thursday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $14.00.

Journey Medical Price Performance

Shares of NASDAQ:DERM opened at $6.72 on Monday. The business's 50 day simple moving average is $6.61 and its two-hundred day simple moving average is $6.59. The firm has a market cap of $185.00 million, a P/E ratio of -30.55 and a beta of 1.08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56.

Institutional Trading of Journey Medical

Institutional investors have recently made changes to their positions in the company. Bank of America Corp DE raised its holdings in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company's stock valued at $30,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Journey Medical during the second quarter worth about $36,000. JPMorgan Chase & Co. purchased a new position in Journey Medical during the second quarter worth about $41,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Journey Medical in the 2nd quarter worth about $48,000. Finally, Royal Bank of Canada increased its stake in Journey Medical by 42.7% in the 1st quarter. Royal Bank of Canada now owns 8,175 shares of the company's stock valued at $38,000 after buying an additional 2,446 shares during the last quarter. Institutional investors own 7.25% of the company's stock.

Journey Medical News Roundup

Here are the key news stories impacting Journey Medical this week:

• Positive Sentiment: Emrosi momentum remains strong: Journey Medical said Emrosi revenue reached $8.1 million, with sales rising 20% sequentially. Management also highlighted 38% high-quality insurance coverage and indicated that average selling price gains could continue in the second half of 2026, supporting growth and profitability. Journey Medical signals continued ASP gains in 2H 2026
• Positive Sentiment: Analyst price target raised: B. Riley reaffirmed its “Buy” rating and increased its price target to $15 from $12, implying substantial potential upside from recent trading levels. B. Riley rating and price target report
• Positive Sentiment: Second-quarter results exceeded expectations: Journey Medical reported adjusted earnings of a $0.01-per-share loss, ahead of the $0.02 loss analysts expected, while revenue of $18.51 million topped the $18.36 million consensus estimate. The results and Emrosi growth reinforce the company’s near-term operating momentum. Journey Medical second-quarter 2026 results
• Negative Sentiment: HC Wainwright lowered multiple earnings forecasts: The firm reduced its 2026 third- and fourth-quarter EPS estimates to $0.01 and $0.02, respectively, and cut its FY2027-FY2030 forecasts. The revisions suggest analysts expect a slower earnings ramp than previously projected, despite maintaining a $0.17 current-year consensus estimate. Journey Medical earnings estimate revisions

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company's product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source